Early diagnosis and intervention can improve outcomes for children with autism spectrum disorder but arriving at a diagnosis can be difficult at an early age. To diagnose the condition, doctors have relied on behavioral tests and the average age of diagnosis in the United States is more than 4 years. NeuroPointDX has developed a diagnostic test that looks at metabolic imbalances in the blood that can diagnose a child with the condition as young as 18 months. We spoke to Elizabeth Donley, CEO of Stemina Biomarker Discovery and NeuroPointDX, about the condition, how the company’s test works, and what it might suggest about the biology of the condition.